Filing Analysis
Carlsmed, Inc. announced the departure of CFO Leo Greenstein and the appointment of Richard Heppenstall as the new CFO. The transition includes a separation agreement for the outgoing CFO and a comprehensive compensation and relocation package for the incoming CFO.
🚩 Red Flags
- Executive turnover (CFO departure) can create operational instability during transition periods.
- Significant cash and equity outflows related to the departure and recruitment of the CFO.
📋 Key Facts
- CFO Leo Greenstein departed effective September 25, 2026; departure is not due to disagreements regarding accounting or internal controls.
- Greenstein to receive $500,000 in cash severance (12 months of base salary) and a pro-rated 2026 incentive award.
- Greenstein to receive accelerated vesting of various equity awards, including 32,856 restricted shares and 19,176 shares via options.
- Greenstein will serve as an advisor through December 31, 2026, for a fee of $60,000.
- Richard Heppenstall appointed CFO effective September 28, 2026; previously EVP/CFO at ZimVie Inc.
- Heppenstall's compensation includes a $500,000 base salary and $2.8 million in total value via inducement stock options and RSUs.
- The company provided a relocation and transition benefit agreement for Heppenstall up to $150,000.
Carlsmed, Inc. announced the appointment of Jeffrey Bertolini as Chief Operating Officer, effective September 8, 2026. Mr. Bertolini previously served as the company's Senior Vice President of Operational Excellence.
📋 Key Facts
- Jeffrey Bertolini appointed as Chief Operating Officer effective September 8, 2026.
- Mr. Bertolini's annual base salary increased to $475,000 as part of the new role.
- Target incentive opportunity increased to 60% of base salary.
- Granted 50,000 stock options to purchase shares of the Company's common stock.
- Mr. Bertolini previously held roles as SVP of Operational Excellence and VP of Advanced Manufacturing Technologies at Carlsmed.
Carlsmed, Inc. filed an 8-K to announce the release of its financial results for the quarter ended June 30, 2026. The filing serves as a formal vehicle to furnish the press release containing these results.
📋 Key Facts
- Report date: August 5, 2026
- Reporting period: Quarter ended June 30, 2026
- The company is an emerging growth company and has elected not to use the extended transition period for new financial accounting standards.
- Financial results were released via press release (Exhibit 99.1).
Carlsmed, Inc. filed an 8-K to announce the issuance of its quarterly financial results for the period ended September 30, 2025.
📋 Key Facts
- The filing was made on November 6, 2025.
- Report covers financial results for the quarter ended September 30, 2025.
- Company is an emerging growth company.
- Financial results were released via press release (Exhibit 99.1).
Carlsmed, Inc. entered into a Fifth Amendment to its Loan and Security Agreement with Customers Bank, restructuring its credit facility. The amendment includes a $50 million term loan and a $10 million revolving line of credit, while also modifying existing warrants issued to the lender.
🚩 Red Flags
- Restrictive covenant requiring a minimum $20.0 million cash balance in a specific bank account.
- Contingent debt tranches ($17.5M) tied to revenue milestones, indicating potential liquidity pressure if growth targets are missed.
- Requirement to achieve certain revenue thresholds if cash on deposit falls below 100% of outstanding debt.
📋 Key Facts
- Entered into Fifth Amendment to Loan and Security Agreement on October 29, 2025.
- Credit facility includes a term loan up to $50.0 million (with $17.5 million contingent on revenue milestones) and a $10.0 million non-formula revolving line of credit.
- Interest rate is the greater of WSJ Prime Rate + 0.25% or 5.25% (currently 7.50%).
- Term loan matures October 15, 2030; interest-only period through October 15, 2027.
- Company must maintain at least $20.0 million in cash in an operating account with Customers Bank at all times.
- Amended warrants: Reduced the number of shares exercisable under Series B and Series C warrants, cancelling contingent rights to 15,831 shares of Common Stock.
Carlsmed, Inc. filed an 8-K to announce the release of its financial results for the quarter ended June 30, 2025. The filing serves as a formal notice that earnings data is being furnished via a press release.
📋 Key Facts
- Report date: August 28, 2025
- Reporting period: Quarter ended June 30, 2025
- The company issued a press release (Exhibit 99.1) containing the financial results.
- Registrant is an emerging growth company.
Carlsmed, Inc. has amended and restated its Certificate of Incorporation and Bylaws in connection with the closing of its initial public offering (IPO). This filing is a standard administrative requirement following an IPO to update corporate governance documents.
📋 Key Facts
- The company closed its initial public offering (IPO) around July 24, 2025.
- Amended and restated Certificate of Incorporation became effective on July 24, 2025.
- Amended and restated Bylaws became effective on July 24, 2025.
- The changes were made in connection with the closing of the IPO as described in a prospectus dated July 22, 2025.